Wire open Last filed Employer GLP 1 coverage for weight loss stalls at 18 percent in KFF survey RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
RoutineREGNews

WADA 2027 Prohibited List keeps semaglutide and tirzepatide permitted for athletes

WADA left the status of GLP 1 drugs unchanged for 2027. Semaglutide and tirzepatide stay legal for athletes and on its Monitoring Program while two studies look at their effects in sport.

MONTREAL

1 Jan 2027Date the 2027 Prohibited List takes effect with semaglutide and tirzepatide still permitted
  1. What's newWADA left the status of GLP 1 receptor agonists unchanged in its 2027 Prohibited List, so semaglutide and tirzepatide stay permitted for athletes and remain on the Monitoring Program.
  2. Why it mattersWADA says the evidence is too thin to show the drugs meet its criteria for a ban, which means athletes with a prescription face no sanction or exemption process in 2027.
  3. What's nextOne WADA funded study is under way and a second has started. An athlete guide is due in December and the list takes effect on 1 January 2027.

Also on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. IND · 27 Oct 2026The 2026 KFF Employer Health Benefits Survey finds GLP 1 coverage for weight loss flat at 18% of firms with 200 or more workers, with 40% of covering firms now requiring a lifestyle program or counselling.
  2. REG · 27 Oct 2026WADA left the status of GLP 1 receptor agonists unchanged in its 2027 Prohibited List, so semaglutide and tirzepatide stay permitted for athletes and remain on the Monitoring Program.
  3. SAF · 27 Oct 2026University of Queensland researchers say people who inject online peptides need needle program access and basic safety advice, and they set out five safety basics.
  4. TRL · 27 Oct 2026Dong-A ST presented ex vivo skin and animal data on a topical formulation of icotrokinra, the oral IL 23 receptor blocking peptide approved by the FDA in March 2026.
  5. SAF · 26 Oct 2026A JAMA Viewpoint by three Center for Science in the Public Interest researchers says the July advisory committee vote to add six peptides to the 503A Bulks List threatens the drug approval process and patients.

By the numbers

The one figure each story turns on.

28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty-liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Head to head, tirzepatide beats semaglutide on weight loss 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 200+Peptide related hospitalisations in NSW in September 2026, up from five in July 2025, as cited by the authors SAF · 27 OCT · Peptide injectors need needle programs and safety advice say Queensland researchers 6 of 7Peptides the FDA compounding advisory committee backed for the 503A Bulks List in July 2026 SAF · 26 OCT · JAMA Viewpoint warns peptide compounding vote threatens the FDA approval system

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Copies, risks and rules

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Oct 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Oct 2026

  • 22 DECThe first GLP-1 pill for weight management gets the green light
  • 11 DECRetatrutide posts the largest average weight loss yet in a phase 3 trial

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Oct 2026

  • 24 NOVSemaglutide fails to slow Alzheimer's in two large trials
  • 15 AUGWegovy gets accelerated approval for fatty-liver disease with scarring

Desk fronts

REGRegulators7
TRLTrials15
INDIndustry5
SAFSafety10
EXPExplainers2

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator10
  • Journal7
  • Company release10
  • Conference5
  • Our newsroom7